{"id":869,"date":"2015-11-27T12:45:00","date_gmt":"2015-11-27T01:45:00","guid":{"rendered":"https:\/\/www.athero.org.au\/fh\/novel-therapies\/"},"modified":"2019-07-29T18:17:56","modified_gmt":"2019-07-29T08:17:56","slug":"novel-therapies","status":"publish","type":"page","link":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/","title":{"rendered":"Novel therapies"},"content":{"rendered":"<p><a href=\"#ldl\">Lipoprotein apheresis <\/a>| <a href=\"#pcsk9inhibitors\">PCSK9 inhibitors<\/a><\/p>\n<h3><a name=\"ldl\"><\/a>Lipoprotein apheresis<\/h3>\n<ul>\n<li>Lipoprotein Apheresis (LA) is an extracorporeal treatment that removes ApoB-containing lipoproteins from the circulation and is usually performed at a transfusion medicine or haemodialysis centre.<\/li>\n<\/ul>\n<ul>\n<li>For patients who require LA, the earlier they are started the better the prognosis. In HoFH patients ideally by age 5 and not later than 8 years.<\/li>\n<\/ul>\n<ul>\n<li>Expected LDL cholesterol reductions:\n<ul>\n<li>acute \u2013 LDL cholesterol level reduction of 55 \u2013 70% can be achieved by a single treatment<\/li>\n<li>long-term treatment \u2013 weekly or fortnightly can achieve close to normal LDL cholesterol values.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li>Statin and other drug therapies (e.g. Ezetimibe, Niacin) should be continued during LA.<\/li>\n<\/ul>\n<ul>\n<li>Concomitant therapy with an ACE inhibitor is contraindicated owing to the risk of hypotension.<\/li>\n<\/ul>\n<ul>\n<li>The removal of LDL in this high risk category improves:\n<ul>\n<li>CHD outcomes \u2013 e.g. angina pectoris<\/li>\n<li>progression of atherosclerosis and aortic fibrosis<\/li>\n<li>endothelial function and markers of inflammation.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li>Indications:\n<ul>\n<li>HoFH patients<\/li>\n<li>compound HeFH patients<\/li>\n<li>severe HeFH patients with progressive CHD who are refractory or intolerant to maximal cholesterol lowering medication<\/li>\n<li>during pregnancy where patients have severely elevated LDL cholesterol levels as in HoFH patients with established CHD.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3><a name=\"pcsk9inhibitors\"><\/a>PCSK9 inhibitors<\/h3>\n<ul>\n<li>Optimal reduction in plasma levels of LDL cholesterol is not achievable in many FH patients.\u00a0<\/li>\n<\/ul>\n<ul>\n<li>Substantial reduction in patient LDL cholesterol has been achieved through the development of highly innovative treatments, such as PCSK9 monoclonal antibodies, used in conjunction with standard therapy.<\/li>\n<\/ul>\n<ul>\n<li>Monoclonal antibodies prevent the binding of PCSK9 to the LDL receptor, thereby preventing degradation of the LDL receptor and increasing the availability of LDL receptors on the cell surface to clear LDL from the circulating blood.<\/li>\n<\/ul>\n<ul>\n<li>PCSK9 inhibitors have been shown to reduce LDL cholesterol levels by up 70%, can be given with statin therapy and are administered by subcutaneous injection fortnightly or monthly.<\/li>\n<\/ul>\n<ul>\n<li>Studies have shown no serious side effects and those displayed are injection site related.<\/li>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Lipoprotein apheresis | PCSK9 inhibitors Lipoprotein apheresis Lipoprotein Apheresis (LA) is an extracorporeal treatment that removes ApoB-containing lipoproteins from the circulation and is usually performed at a transfusion medicine or haemodialysis centre. For patients who require LA, the earlier they are started the better the prognosis. In HoFH patients ideally by age 5 and not &hellip; <a href=\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Novel therapies<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":858,"menu_order":420,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_links_to":"","_links_to_target":""},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.7.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novel therapies - FH Australasia Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel therapies - FH Australasia Network\" \/>\n<meta property=\"og:description\" content=\"Lipoprotein apheresis | PCSK9 inhibitors Lipoprotein apheresis Lipoprotein Apheresis (LA) is an extracorporeal treatment that removes ApoB-containing lipoproteins from the circulation and is usually performed at a transfusion medicine or haemodialysis centre. For patients who require LA, the earlier they are started the better the prognosis. In HoFH patients ideally by age 5 and not &hellip; Continue reading Novel therapies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"FH Australasia Network\" \/>\n<meta property=\"article:modified_time\" content=\"2019-07-29T08:17:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/\",\"url\":\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/\",\"name\":\"Novel therapies - FH Australasia Network\",\"isPartOf\":{\"@id\":\"https:\/\/www.athero.org.au\/fh\/#website\"},\"datePublished\":\"2015-11-27T01:45:00+00:00\",\"dateModified\":\"2019-07-29T08:17:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/#breadcrumb\"},\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.athero.org.au\/fh\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health Professionals\",\"item\":\"https:\/\/www.athero.org.au\/fh\/health-professionals\/what-is-familial-hypercholesterolaemia-fh\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Novel therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.athero.org.au\/fh\/#website\",\"url\":\"https:\/\/www.athero.org.au\/fh\/\",\"name\":\"FH Australasia Network\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.athero.org.au\/fh\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-AU\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novel therapies - FH Australasia Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Novel therapies - FH Australasia Network","og_description":"Lipoprotein apheresis | PCSK9 inhibitors Lipoprotein apheresis Lipoprotein Apheresis (LA) is an extracorporeal treatment that removes ApoB-containing lipoproteins from the circulation and is usually performed at a transfusion medicine or haemodialysis centre. For patients who require LA, the earlier they are started the better the prognosis. In HoFH patients ideally by age 5 and not &hellip; Continue reading Novel therapies","og_url":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/","og_site_name":"FH Australasia Network","article_modified_time":"2019-07-29T08:17:56+00:00","twitter_card":"summary","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/","url":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/","name":"Novel therapies - FH Australasia Network","isPartOf":{"@id":"https:\/\/www.athero.org.au\/fh\/#website"},"datePublished":"2015-11-27T01:45:00+00:00","dateModified":"2019-07-29T08:17:56+00:00","breadcrumb":{"@id":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/#breadcrumb"},"inLanguage":"en-AU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.athero.org.au\/fh\/health-professionals\/novel-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.athero.org.au\/fh\/"},{"@type":"ListItem","position":2,"name":"Health Professionals","item":"https:\/\/www.athero.org.au\/fh\/health-professionals\/what-is-familial-hypercholesterolaemia-fh\/"},{"@type":"ListItem","position":3,"name":"Novel therapies"}]},{"@type":"WebSite","@id":"https:\/\/www.athero.org.au\/fh\/#website","url":"https:\/\/www.athero.org.au\/fh\/","name":"FH Australasia Network","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.athero.org.au\/fh\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-AU"}]}},"_links":{"self":[{"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/pages\/869"}],"collection":[{"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/comments?post=869"}],"version-history":[{"count":21,"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/pages\/869\/revisions"}],"predecessor-version":[{"id":3006,"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/pages\/869\/revisions\/3006"}],"up":[{"embeddable":true,"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/pages\/858"}],"wp:attachment":[{"href":"https:\/\/www.athero.org.au\/fh\/wp-json\/wp\/v2\/media?parent=869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}